Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Derivatives used in the treatment of muscle atrophy

A technology of muscle atrophy and derivatives, which is applied in muscular system diseases, neuromuscular system diseases, drug combinations, etc., and can solve problems such as side effects and unsatisfactory effects

Active Publication Date: 2018-02-23
METABRAIN RES
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Existing experimental treatments for sarcopenia rely on nutritional modalities, physical exercise, appetite stimulants, or the use of anabolic compounds such as testosterone, but the results of these treatments have been unsatisfactory (Morley et al, 2007), and may cause side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Derivatives used in the treatment of muscle atrophy
  • Derivatives used in the treatment of muscle atrophy
  • Derivatives used in the treatment of muscle atrophy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0097] The invention will be better understood from the following figures and description of examples, which are given by way of non-limiting description.

Description of drawings

[0098] figure 1 Myofiber diameters (μm) are visualized in the presence of vehicle (control: Ctrl) and compound 1 at a concentration of 10 μM, dexamethasone (DEX) at a concentration of 10 μM and IGF1 at a concentration of 10 ng / ml.

[0099] cascade filter

[0100] Screening tests were developed from work in the literature and based on the pathological features of sarcopenia. At the pathophysiological level, the disease is characterized by decreased protein synthesis and increased proteolysis. Thus, the above-mentioned compounds were screened by means of an assay allowing to evaluate the inhibition of the gene expression of myostatin by chemical molecules and their enhancement of the protein synthesis capacity in muscle cells. Furthermore, we have shown that some of the products listed above incr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to View More

Abstract

The invention relates to a derivative of general formula (I), or an enantiomer, diastereoisomer, hydrate, solvate, tautomer, racemic mixture or pharmaceutically acceptable salt thereof for use as a medicament for the treatment and / or prevention of muscle atrophy in mammals and / or to limit muscle atrophy in mammals and / or to stimulate muscle growth in mammals doing exercise and aiming to increase muscle mass and quality, as prevention against the onset of age-related symptoms of sarcopenia or for rehabilitation following muscle loss, muscle atrophy being related to age and / or to the consequences of drug treatment and / or immobilisation and / or cachexia.

Description

technical field [0001] The present invention relates to derivatives useful in the treatment of diseases associated with muscle wasting. Background technique [0002] Today, there is a marked lack of new treatments to delay the onset and progression of age-related disorders and diseases that are accompanied by a decline in muscle strength or power (such as sarcopenia) and mobility problems associated with aging is a very serious problem with wide-ranging health consequences. [0003] Older adults with certain metabolic disorders or diseases often face loss of lean body mass due at least in part to decreased muscle protein synthesis (eg, sarcopenia), decreased nutrient intake, or the presence of inflammation. Decreased lean body mass is known to be associated with fatigue, reduced ability to perform tasks required of daily living, increased risk of fractures, increased falls and hospitalizations, impaired metabolism (glucose tolerance, insulin sensitivity) and cognitive and l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/197A61K31/4402A61K31/50A61K31/165A61K31/495A61K31/4406A61K31/216A61P21/00A61P21/06
CPCA61K31/165A61K31/197A61K31/216A61K31/4402A61K31/4406A61K31/495A61K31/50A61K31/15A61P21/00
Inventor 索菲·N·雷纳尔米舍利娜·R·凯尔格特瓦莱里·奥捷克里斯汀·G·沙龙珍-丹尼斯·迪朗弗兰克·F·莱皮弗里安尼克·M·奥代
Owner METABRAIN RES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com